Syngene International

As regulators ease biosimilar trial norms, Syngene International is expanding into late-stage clinical supply production, betting on biologics and peptide manufacturing for growth

Revenue up 2% YoY to Rs 926 crore as research services offset biologics inventory correction; company maintains FY26 guidance

Jefferies is optimistic on India's CRDMO sector, given its evolution from quasi-chemical firms into strategic partners for innovators; check more details

Syngene's Q1 FY26 profit rose to Rs 87 crore as Research Services drove contract conversions, while operational revenue rose 11 per cent to Rs 875 crore

Syngene's stock fell as much as 10 per cent during the day to ₹674.25 per share, the worst intraday loss atleast in over five years

Furthermore, Biocon has scheduled a board meeting on April 4 to discuss and approve fundraising for its commercial business

The facility, which the contract research firm said is strategically located near key biotech hubs in the Northeast US, is expected to be operational for client projects from the second half of 2025

The facility, equipped with multiple monoclonal antibody (mAbs) manufacturing lines, comes for a deal value of $36.5 million

Pharma stocks list: Divis Labs share price rallied 1.9% intraday, Suven Pharma share price surged 4.6%, Blue Jet Healthcare share price added 4.9%, and Syngene International share price rose 1.5%

During the quarter, Discovery Services launched "China+1" pilots with large and mid-size pharma companies and converted them into long-term contracts. Growth signals stabilizing

Reports suggest promoter Biocon was likely to sell a 2 per cent stake in the company via block deals

Syngene plans to expand its capacity and capabilities at its Bangalore and Hyderabad campuses to meet anticipated long-term demand

Derivatives market update for Sept 06: The Nifty PCR dipped from 0.74, while Bank Nifty to 0.78; reflecting a cautionary trend said Dhupesh Dhameja of SAMCO Securities. Max Financial see short buildup

Derivative market update for Monday, Sept 02: FIIs long-short ratio in index futures rose to 2.6:1, implying 5 longs for every 2 shorts. Bandhan Bank, Syngene and Granules India see long buildup.

The company plans to expand research and manufacturing facilities, allocates Rs 500 cr capex for FY25

Goldman Sachs attributes India's underpenetrated CDMO and CRO market to smaller capacities, lack of Innovation with little collaboration between Industry and academia

About a week ago, Syngene International's share price declined by 3 per cent following UBS Global Research stock downgrade to sell

Contract research and manufacturing services firm Syngene International Ltd on Thursday reported 1.64 per cent growth in consolidated net profit at Rs 111.5 crore in the third quarter ended December 2023, impacted by reduced funding in the US biotech segment and transaction costs of the acquisition of a multi-modal facility from Stelis Biopharma. The company had posted a profit of Rs 109.7 crore in the third quarter of last fiscal, Syngene International said in a regulatory filing. Consolidated revenue from operations during the quarter under review stood at Rs 853.5 crore as against Rs 785.9 crore in the year-ago period, it added. Total expenses in the third quarter were higher at Rs 740.9 crore as compared to Rs 663.2 crore in the same period a year ago, Syngene International said. The company incurred transaction costs of Rs 3.7 crore in the quarter ended December 2023 relating to the acquisition of multi-modal facility (Unit 3) from Stelis Biopharma Ltd (SBL) and the same has b

Syngene International Ltd on Tuesday reported a 14.22 per cent increase in consolidated net profit at Rs 116.5 crore in the September quarter. The company had posted a consolidated net profit of Rs 102 crore in the year-ago period, Syngene International said in a regulatory filing. Consolidated revenue from operations were at Rs 910.1 crore as compared to Rs 768.1 crore in the year-ago period, it added. The company's total expenses rose to Rs 773.6 crore in the second quarter of the current fiscal as against Rs 653.5 crore a year ago. Syngene International Managing Director and CEO Jonathan Hunt said the company posted strong results for the second quarter and first half of the ongoing financial year, particularly in its development and manufacturing services. "In development services, we also added a new non-GMP capability centre to meet market demand for agile, cost-efficient, early phase development and scale-up services," he said. "In manufacturing, we made good progress on o

Contract manufacturing services firm Syngene International on Wednesday said its consolidated net profit increased 26 per cent to Rs 93 crore in the June quarter. The company had reported a net profit of Rs 74 crore in the April-June quarter of last fiscal. Revenue rose to Rs 832 crore for the first quarter of the current fiscal as against Rs 660 crore in the year-ago period, Syngene International said in a regulatory filing. Syngene International Chief Financial Officer Sibaji Biswas said the financial performance of the company is in line with the revenue growth guidance for the year on a constant currency basis. "We made investments in growing our portfolios in biologics manufacturing and discovery services. Despite these investments, the company will continue to maintain a strong balance sheet and a low debt profile," he added. Shares of the company on Wednesday ended 1.84 per cent down at Rs 761.65 apiece on the BSE.